Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
ID: 344815Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $200K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Animal Models and Related Biological Materials for Down Syndrome Research" (FOA Number PAR-23-067). This initiative aims to foster innovative and exploratory research to enhance the understanding of Down syndrome (DS) by developing new animal models, genetic resources, and informatics technologies, particularly focusing on co-occurring conditions such as autism and cognitive decline. Eligible applicants include higher education institutions, non-profits, and government entities, with grants allowing for up to $200,000 in direct costs annually, totaling $275,000 over two years. Interested parties must submit their applications electronically via Grants.gov by January 7, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "Development of Animal Models and Related Biological Materials for Down Syndrome Research" (FOA Number PAR-23-067). This initiative aims to foster innovative and exploratory research to enhance the understanding of Down syndrome (DS) by developing new animal models, genetic resources, and informatics technologies. The INCLUDE Project seeks to identify and address gaps in existing DS research, focusing on co-occurring conditions such as autism, cognitive decline, and cardiovascular issues. Eligible applicants include higher education institutions, non-profits, and government entities, with grants allowing for up to $200,000 in direct costs annually, for a total of $275,000 over two years. The R21 grant type is specifically designed to encourage high-risk, high-reward research projects that could lead to significant advancements without the need for extensive preliminary data. Applications must adhere to strict guidelines regarding submission processes, including electronic submission via Grants.gov and compliance with NIH policies on data management. Review criteria will consider innovation, significance, approach, and investigator qualifications. This announcement underscores NIH's commitment to improving health outcomes and quality of life for individuals with Down syndrome through collaborative and rigorous scientific inquiry.
    Similar Opportunities
    Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Animal Models and Related Biological Materials for Down Syndrome Research" under the INCLUDE Project. This initiative aims to support exploratory and innovative research focused on developing and characterizing animal models and biological materials that are essential for Down syndrome (DS) studies, with an emphasis on improving access to these resources and enhancing the rigor of preclinical research. The funding opportunity is particularly significant as it addresses critical gaps in DS research, encouraging projects that utilize advanced technologies such as artificial intelligence and machine learning. Eligible applicants can receive up to $200,000 for a two-year project period, with applications due in March, June, October, and February each year, and the announcement set to expire on January 8, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the INCLUDE Project, specifically for Clinical Trials Phased Awards aimed at advancing research on Down syndrome. This grant program encourages Exploratory/Developmental Phased Innovation (R61/R33) applications to develop clinical trials addressing critical health conditions associated with Down syndrome, with a focus on milestone-driven research. The total funding available for this initiative is approximately $3 million, with an expected four awards, and applications may request a minimum of $100,000. Interested applicants should note that the project period can extend up to five years, with the R61 phase supporting preliminary studies for up to two years, followed by a potential R33 phase for clinical trial support. For further inquiries, applicants can contact Laurie Ryan, PhD, at 301-496-9350 or via email at ryanl@nih.gov. The application deadline is set for February 19, 2026, with awards anticipated to be announced by September 1, 2026.
    INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome, aimed at enhancing health and quality of life for individuals with Down syndrome. This funding opportunity invites researchers to propose innovative exploratory and developmental projects that address critical needs identified in the INCLUDE Project objectives, potentially leading to breakthroughs in biomedical, behavioral, or clinical research. The total estimated program funding is $1 million, with individual awards ranging from $50,000 to $200,000, and the application process is open to a diverse range of eligible applicants, including tribal governments and community-based organizations. Interested parties should contact Dr. Melissa Parisi at 301-728-1861 or via email at parisima@mail.nih.gov for further information, with applications due by February 19, 2026, and awards expected to be announced by September 1, 2026.
    INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Transformative Research Awards for Down syndrome, aimed at advancing innovative research to improve health and quality of life for individuals with Down syndrome. This funding opportunity invites applications for groundbreaking research that can establish new scientific paradigms or develop transformative technologies related to Down syndrome and its co-occurring conditions, with no preliminary data required. The program has an estimated total funding of $3 million, with individual awards ranging from $250,000 to $500,000, and is expected to support approximately four projects. Interested applicants can reach out to Dr. Charlene Schramm at schrammc@nih.gov or by phone at 301-402-3793, with applications due by February 19, 2026, and anticipated awards announced by September 1, 2026.
    Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the development of animal models and related biological materials for research, designated as an R21 Exploratory/Developmental Research Grant. This funding initiative aims to support innovative projects that enhance, characterize, and preserve animal models relevant to human health and diseases, with a focus on studies that encompass multiple body systems or disease categories rather than single-disease research. The total funding available is $200,000, with a project period limited to two years, and applications are due by January 7, 2028. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-273.html.
    Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)." This initiative invites applications to utilize existing biospecimens to generate integrated genomic and multi-omics data aimed at uncovering the molecular mechanisms associated with health conditions related to Down syndrome. The program emphasizes the importance of including cohorts from underrepresented racial and ethnic groups and does not provide direct funding; instead, it facilitates access to sequencing resources for various genomic profiling techniques. Interested applicants should note that the earliest submission date is February 13, 2024, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html.
    INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Fellow Transition Award (F99/K00), aimed at recruiting exceptional graduate students for Down syndrome-related research. This opportunity invites interdisciplinary applications from diverse fields such as genetics, biochemistry, data science, imaging, engineering, and neurobiology, providing two phases of support: the F99 phase for 1-2 years of dissertation research, followed by the K00 phase for up to 4 years of mentored postdoctoral training. The NIH plans to commit $1.5 million in FY2025 for up to 20 awards, contingent on the quality of applications, with a submission deadline of July 1, 2026. Interested applicants are encouraged to contact the NIH Grants Information at grantsinfo@nih.gov for further inquiries and to review the full announcement at NIH Grants.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the establishment of Animal and Biological Material Resource Centers under the Notice of Funding Opportunity (NOFO) RFA-OD-25-011. This initiative aims to support the creation, preservation, and distribution of high-quality laboratory animals and biological materials, while also integrating new approach methodologies (NAMs) that complement traditional animal-based research. The program is crucial for enhancing research infrastructure and ensuring the availability of resources that facilitate scientific rigor and reproducibility in biomedical research. A total funding amount of $1.3 million is anticipated to support at least two awards annually from FY 2023-2025, with applications due by January 9, 2029. Interested applicants can reach out to the Office of Research Infrastructure Programs at ORIPDCM@mail.nih.gov for further information.